Age, Biography and Wiki

Francesco De Rubertis was born on 23 January, 1970 in Italy, is a Venture capitalist. Discover Francesco De Rubertis's Biography, Age, Height, Physical Stats, Dating/Affairs, Family and career updates. Learn How rich is he in this year and how he spends money? Also learn how he earned most of networth at the age of 54 years old?

Popular As N/A
Occupation Partner at medicxi
Age 54 years old
Zodiac Sign Aquarius
Born 23 January, 1970
Birthday 23 January
Birthplace Italy
Nationality Italy

We recommend you to check the complete list of Famous People born on 23 January. He is a member of famous with the age 54 years old group.

Francesco De Rubertis Height, Weight & Measurements

At 54 years old, Francesco De Rubertis height not available right now. We will update Francesco De Rubertis's Height, weight, Body Measurements, Eye Color, Hair Color, Shoe & Dress size soon as possible.

Physical Status
Height Not Available
Weight Not Available
Body Measurements Not Available
Eye Color Not Available
Hair Color Not Available

Who Is Francesco De Rubertis's Wife?

His wife is Divorced from Sandra Henchoz since 2018

Family
Parents Not Available
Wife Divorced from Sandra Henchoz since 2018
Sibling Not Available
Children Not Available

Francesco De Rubertis Net Worth

His net worth has been growing significantly in 2023-2024. So, how much is Francesco De Rubertis worth at the age of 54 years old? Francesco De Rubertis’s income source is mostly from being a successful . He is from Italy. We have estimated Francesco De Rubertis's net worth, money, salary, income, and assets.

Net Worth in 2024 $1 Million - $5 Million
Salary in 2024 Under Review
Net Worth in 2023 Pending
Salary in 2023 Under Review
House Not Available
Cars Not Available
Source of Income

Francesco De Rubertis Social Network

Instagram
Linkedin
Twitter Francesco De Rubertis Twitter
Facebook
Wikipedia Francesco De Rubertis Wikipedia
Imdb

Timeline

1970

Francesco De Rubertis (born January 23, 1970) is a partner at medicxi, a venture capital firm with offices in London, Jersey and Geneva, having co-founded the firm in February 2016.

1997

Prior to that he was a partner at another venture capital firm, Index Ventures, having led the firm's efforts to establish its life sciences practice after joining in 1997.

De Rubertis was born in Italy.

He graduated from the University of Pavia with a Bachelor of Arts in Genetics and Microbiology, before earning a Ph.D. in Molecular Biology from the University of Geneva, where he also met his wife, Sandra Henchoz, who was a fellow student.

De Rubertis engaged in postdoctoral research in molecular genetics at the Whitehead Institute at Massachusetts Institute of Technology (MIT), and later earned the Chartered Financial Analyst (CFA) designation.

After his postdoctoral work at MIT, in 1997 De Rubertis moved back to Geneva, where he joined Index Ventures and helped co-found the firm's life sciences practice.

2009

In 2009 he moved to London (site of another Index office) where he continues to reside.

De Rubertis is responsible for all of Index Ventures’ investments in the life sciences.

He has served on the Boards of Directors of many companies, including Addex Therapeutics (swx: ADXN), CellZome (acquired by GlaxoSmithKline for $120 Million ), Genmab (omx: CSE11143 GEN), Molecular Partners (swx: MOLN), PanGenetics (acquired by Abbott Laboratories), and Parallele Bioscience (acquired by Affymetrix).

2010

In 2010 De Rubertis was named by BioWorld as one of 28 "movers and shakers" predicted to shape the biotechnology industry over the next two decades

.

2012

In 2012 De Rubertis spearheaded the launch of Index Ventures’ $200 Million life sciences fund in partnership with GlaxoSmithKline (GSK) and Johnson & Johnson (J&J), to invest in early-stage biotechnology companies

.

De Rubertis is the author of several publications in international scientific journals.

In October 2012 De Rubertis was named by Xconomy as one of 40 of “Young and Proven” biotech venture capitalists.

De Rubertis is a member of the Strategic Advisory Board of the University of Geneva.

2016

In February 2016 De Rubertis launches an independent venture capital firm Medicxi (formerly Index Ventures Life Sciences) and announces the closing of Medicxi Ventures 1 (MV1) a €210m fund including GSK and Johnson & Johnson Innovation.

Medicxi is managed by four Partners Francesco de Rubertis, Kevin Johnson, David Grainger and Michèle Ollier all of whom previously led the Life Sciences practice at Index Ventures.

2017

On November 30, 2017 De Rubertis was named in the Bloomberg Top 50 most influential people of 2017.

He was selected as one of 10 nominees in the Tech (& Science) category along with Elon Musk (Tesla, SpaceX), Masayoshi Son (SoftBank Group) and Martin Lau (Tencent Holdings).

The Bloomberg Top 50 consists of 5 categories Tech (& Science), Business, Politics, Finance and Entertainment.

De Rubertis's reputation for halving the time it takes for a return on biotech investments has Silicon Valley eager to get in on a $300 million fund he's raised for late-stage startups.

Medicxi Growth 1, which made its first investments in health care and diabetes treatments, is taking minority stakes in companies that are developing multiple therapies, have full management teams, and intend to go public as independent businesses.

This is a departure for De Rubertis.

He has focused on “skinny” startups—with small management teams and only one therapy—that can integrate into larger companies after being bought.

The shift hasn't diminished interest in the fund.

Verily, Alphabet Inc.’s life-sciences arm, has also invested in MG-1